Supernus, Inc. SUPN
28.35 USD -0.61 (-2.11%)
Regular-session close
28.35 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
28.32 Day range 29.37
25.92 52-week range 42.81
- YTD
- -20.99%
- 1 year
- -13.04%
News
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.benzinga.com B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 B of A Securities analyst Chi Fong initiates coverage on Supernus (NASDAQ:SUPN) with a Buy rating and announces Price Target of $47.
benzinga.com Piper Sandler Reinstates Overweight on Supernus, Announces $47 Price Target Piper Sandler analyst David Amsellem reinstates Supernus (NASDAQ:SUPN) with a Overweight and announces $47 price target.
benzinga.com Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for FRSH, EW, ATRC, SUPN and DUOL; cut targets for FLG and AMD. EW was upgraded, while FLG was downgraded.benzinga.com Cantor Fitzgerald Maintains Overweight on Supernus, Raises Price Target to $87 Cantor Fitzgerald analyst Kristen Kluska maintains Supernus (NASDAQ:SUPN) with a Overweight and raises the price target from $67 to $87.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
benzinga.com Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.
benzinga.com Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses…
benzinga.com MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20261022-1485639/1485639_msgs-supn-6.pdf
benzinga.com Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
